HDAC9 and melanoma: Alteration of p53 activity by HDAC inhibitor driven hyperacetylation may alter melanoma resistance to therapy [38,39,40] and NF-κB activation may alter cytokine production, anti-apoptotic protein transcription and immune response [41,42,43].